Licensing, Acquisitions, and Other Arrangements - Schedule of Consideration Paid (Details) - USD ($) $ in Millions	Jun. 01, 2016	Apr. 01, 2016
Stemcentrx
Business Acquisition [Line Items]
Cash	$ 1,883
Fair value of AbbVie common stock	3,923
Contingent consideration	620
Total consideration	$ 6,426
BI
Business Acquisition [Line Items]
Cash		$ 595
Deferred consideration payable		18
Contingent consideration		3,365
Total consideration		$ 3,978